New drug combo tested in battle against Tough-to-Treat gynecologic cancers
NCT ID NCT03586661
Summary
This early-stage study is testing a combination of two drugs, niraparib (a pill) and copanlisib (an IV infusion), for women whose ovarian, endometrial, or related cancers have returned after prior treatment. The main goals are to find the safest dose of this combination and to learn about its side effects. Researchers also want to see if the treatment can help control the growth of tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.